VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
IPHAInnate Pharma S.A.
$1.79$168M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksIPHAQuarterly Financials

Innate Pharma S.A. (IPHA) Quarterly Financials

120+ quarters historyFree accessUpdated daily

Innate Pharma S.A. (IPHA) quarterly income statement — complete revenue, gross profit & net income history

IPHA Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricQ4'25Q2'25Q4'24Q2'24Q4'23Q2'23Q4'22Q2'22Q4'21Q2'21Q4'20Q2'20
Sales/Revenue-2.07M4.86M276K12.35M16.56M35.34M8.31M41.27M2.79M9.32M26.99M36.74M
Revenue Growth %-851.09%-60.63%-98.33%-65.07%99.27%-14.36%197.49%342.87%-89.65%-74.64%55.25%-28.77%
Cost of Goods Sold020.52M-29.08M29.08M24.57M15.73M13.35M12.48M12.9M10.6M4.65M31.5M
COGS % of Revenue-422.22%-10534.78%235.53%148.39%44.5%160.71%30.23%461.8%113.79%17.23%85.72%
Gross Profit18.45M-15.66M29.35M-16.73M-3.13M19.62M-5.04M28.79M-10.11M-1.28M22.34M5.25M
Gross Margin %-889.87%-322.22%10634.78%-135.53%-18.88%55.5%-60.71%69.77%-361.8%-13.79%82.77%14.28%
Gross Profit Growth %-37.15%6.4%1038.96%-185.29%38.03%-31.87%50.08%2340.7%-145.23%-124.49%83.07%-84.24%
Operating Expenses46.45M9.77M54.61M9.58M9.14M36.95M34.73M35.05M31.32M33.71M37.84M13.59M
OpEx % of Revenue-2240.47%200.97%19787.68%77.62%55.23%104.55%417.99%84.94%1121.27%361.69%140.19%37%
Selling, General & Admin1.23M9.77M2.35M9.58M9.14M8.54M9.57M11.37M5.51M13.38M16.05M14.49M
SG&A % of Revenue-59.43%200.97%851.81%77.62%55.23%24.17%115.15%27.55%197.14%143.63%59.47%39.43%
Research & Development22.93M20.52M22.9M29.08M24.57M28.41M25.16M23.68M25.81M20.32M21.79M31.5M
R&D % of Revenue-1106.08%422.22%8298.55%235.53%148.39%80.38%302.84%57.38%924.13%218.06%80.72%85.72%
Other Operating Expenses1000K-1000K1000K-1000K-1000K000000-1000K
Operating Income-28M-25.43M-25.26M-26.31M-7.42M-5.25M-28.8M4.17M-30.9M-26.58M-17.41M-8.35M
Operating Margin %1350.6%-523.19%-9152.9%-213.15%-44.79%-14.86%-346.66%10.12%-1106.37%-285.21%-64.51%-22.72%
Operating Income Growth %-10.83%3.37%-240.64%-400.91%74.25%-225.82%6.79%115.71%-77.47%-218.39%58%-246.23%
EBITDA-27.33M-25.06M-24.02M-25.56M-5.54M-1.61M-26.42M6.22M-28.52M-24.39M-10.85M-1.63M
EBITDA Margin %1318.19%-515.66%-8702.17%-207.07%-33.47%-4.55%-317.99%15.06%-1021.27%-261.69%-40.19%-4.43%
EBITDA Growth %-13.77%1.96%-333.38%-1489.74%79.03%-125.86%7.37%125.49%-162.94%-1397.05%65.83%-113%
D&A (Non-Cash Add-back)671.99K366K1.24M750K1.87M3.65M2.38M2.04M2.38M2.19M6.56M6.72M
EBIT-31.38M-25.43M-22.59M-26.31M-12.27M-2.81M-12.46M4.25M-29.28M-28.47M-60.37M-8.35M
Net Interest Income4.24M564K67K1.94M8.92M641K254K2K2K5.5K26.5K170K
Interest Income7.11M564K101K2.54M11.94M965K348K2K2K5.5K26.5K170K
Interest Expense2.87M034K600K3.02M324K94K00000
Other Income/Expense165K4.08M555K1.55M2.98M2.12M-39.31M-2.14M1.48M-2.07M-43.12M-1.99M
Pretax Income-27.83M-21.34M-24.71M-24.76M-4.43M-3.14M-68.11M2.11M-29.42M-28.65M-60.53M-10.33M
Pretax Margin %1342.64%-439.18%-8951.81%-200.6%-26.78%-8.87%-819.75%5.1%-1053.24%-307.46%-224.27%-28.12%
Income Tax-2.99M0000-4.85M-3.77M-4.27M-7.66M-4.93M-6.88M0
Effective Tax Rate %10.76%0%0%0%0%154.78%5.53%-202.75%26.03%17.22%11.37%0%
Net Income-27.63M-21.34M-24.71M-24.76M-9.29M1.72M-64.41M6.3M-29.09M-23.72M-53.65M-10.33M
Net Margin %1332.71%-439.18%-8951.81%-200.6%-56.1%4.86%-775.14%15.27%-1041.53%-254.52%-198.76%-28.12%
Net Income Growth %-11.82%13.81%-166.01%-1541.44%85.58%-72.74%-121.4%126.57%45.78%-129.52%-57.8%-178.05%
Net Income (Continuing)-27.63M-21.34M-24.71M-24.76M-9.29M1.72M-64.35M6.38M-21.76M-23.72M-53.65M-10.33M
Discontinued Operations000000-29K-73K-1000K000
Minority Interest000000000000
EPS (Diluted)-0.30-0.25-0.30-0.31-0.120.02-0.800.08-0.37-0.30-0.68-0.13
EPS Growth %0%19.35%-150%-1612.2%85%-73.38%-116.22%125.67%45.59%-130.77%-30.77%-165%
EPS (Basic)-0.30-0.25-0.30-0.31-0.120.02-0.800.08-0.37-0.30-0.68-0.13
Diluted Shares Outstanding91.41M86.94M81.05M80.87M80.59M83.78M80.19M81.87M79.54M79M78.93M78.89M
Basic Shares Outstanding91.41M85.38M81.05M79.88M80.59M80.32M80.19M79.74M79.54M79M78.93M78.89M
Dividend Payout Ratio------------